MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC”), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
The enzymes offered for sale are active and validated for use in high-throughput screening assays. In the case of the HMTs those assays employ RBC’s proprietary HotSpot(SM) methodology, which couples economical screening with the data quality of a “gold standard” radiometric approach. HMTs are also routinely assayed by conventional scintillation counting in a plate format (TopCount).
“Our assay expertise is helping us make better enzymes, while the ability to produce new proteins in-house will help us expand the range of assays we can offer, and provide our clients with a more complete drug discovery process,” said Konrad Howitz, RBC’s Director of Epigenetics.
In addition to the HDAC, Sirtuin, HMT, DNMT and HAT assays currently offered, RBC has innovative assays for demethylases and epigenetic readers in active development.
Based in Malvern, PA, RBC has become a premier provider of drug screening and profiling services. With more than 400 kinases, RBC’s coverage of the kinome is the broadest in the industry. Using its proprietary HotSpot(SM) technology and other innovations, RBC is expanding its already substantial coverage of epigenetic regulatory enzymes. RBC has provided its services to over 200 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
For more information, visit: www.reactionbiology.com.
News issued by: Reaction Biology Corporation
Original Image: https://www.send2press.com/wire/images/11-1024-reaction_72dpi.jpg
# # #
Original Story ID: 2011-10-1024-002 (7377) :: 2011-10-1024-002
Original Keywords: Konrad Howitz, HotSpot methodology, Reaction Biology Corporation, drug discovery services in epigenetics, RBC, pharmaceutical, biotech, drug screening and profiling services, histone methyltransferases, Pennsylvania Reaction Biology Corporation Malvern Pennsylvania MALVERN, Pa.
Alternate Headline: Recombinant Methyltransferase Line launched by Reaction Biology Corporation
NEWS ARCHIVE NOTE: this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted/moved (and redirected) into our 3.0 platform. Also note the story “reads” counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published/issued: Mon, 24 Oct 2011 14:25:48 +0000
News Source: Reaction Biology Corporation